Aug 19, 2026 earnings call — TCW deal strengthens Accuray balance sheet
Announced TCW transaction that converts $40 million of debt into convertible preferred equity and includes a $15 million cash investment.
Revenue $0.1B (est $0.1B) · EPS $-0.02 (est $-0.03)
Key quotes
"Under the agreement, TCW will exchange $40 million of existing term debt for convertible preferred equity with an equivalent liquidation preference."
"Recently, we entered into nonbinding letters of intent with Samsung Medison and Research Laboratories while continuing to expand our relationship with Tata Consultancy Services."
"Synchrony remains 1 of the most differentiated capabilities in radiation therapy."